Apexian Pharmaceuticals

About:

Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases.

Top Investors: BioCrossroads, IU Ventures, Elevate Ventures

Description:

Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. It was founded in 2005 and headquartered in Indianapolis, Indiana.

Total Funding Amount:

$6.88M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Indianapolis, Indiana, United States

Founded Date:

2005-01-01

Contact Email:

rmiller(AT)apexianpharma.com

Founders:

Mark R. Kelley

Number of Employees:

1-10

Last Funding Date:

2021-08-31

IPO Status:

Private

Industries: